Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744209 · ClinicalTrials.gov registry record
Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 17
- Enrollment target
NCT02744209: Clinical Trial study, sponsored by Mayo Clinic.
NCT02744209 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744209 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treated with Pembrolizumab.
Primary Outcome
Patient response to therapy will be assessed using RECIST 1.1 criteria at 12 weeks. The investigators will use lymphocyte gene expression data to derive expression profiles that distinguish patients that respond to therapy (complete responses plus partial responses) from patients with disease progression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-01 |
Why NCT02744209 stopped before completion
NCT02744209 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02744209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02744209 about?
NCT02744209 is a clinical study titled "Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients". This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treat...
What is the current status of trial NCT02744209?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2016-04. Estimated completion is 2019-01.
Who is sponsoring clinical trial NCT02744209?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia